Circulating free DNA integrity index and promoter methylation of tumor suppressor gene P16, DAPK and RASSF1A as a biomarker for oropharyngeal squamous cell carcinoma

Kumari, Swati; Mishra, Sridhar; Anand, Nidhi; Hadi, Rahat; Rastogi, Madhup; Husain, Nuzhat

doi:10.1016/j.prp.2023.154489

Cited by 5 publications

(6 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…promoter region is well-documented in various cancers, including HNSCC. [38][39][40][41] The detection of p16 gene hypermethylation is often used as a biomarker for the early diagnosis and prognosis of HNSCC (Figure 2). Methylation-specific polymerase chain reaction (MSP) and other molecular techniques are commonly employed to assess the methylation status of the p16 gene in tumor samples.…”

Section: Genetic Testingmentioning

confidence: 99%

“…Methylation‐specific polymerase chain reaction (MSP) and other molecular techniques are commonly employed to assess the methylation status of the p16 gene in tumor samples 42 . The presence of p16 hypermethylation may indicate an increased risk of HNSCC, and also it can act as a potential therapeutic target 38 . Research has shown that the methylation status of the DAPK gene promoter is altered in HNSCC and is associated to its progression, prognosis, and response to therapy 43 .…”

Section: Diagnosis In Personalized Medicinementioning

confidence: 99%

“…A tumor suppressor gene called RASSF1A controls cell proliferation, apoptosis, and cell cycle progression. Hypermethylation of the RASSF1A gene promoter region can lead to its inactivation, which may contribute to uncontrolled cell growth and tumorigenesis 38 . In the context of HNSCC, the methylation status of the RASSF1A gene has been investigated for its potential as a biomarker for disease detection, prognosis, and treatment response.…”

Section: Diagnosis In Personalized Medicinementioning

confidence: 99%

“…Hypermethylation of the DAPK, MGMT, MSP tumor suppressor gene (also known as CDKN2A or INK4a), Hypermethylation of the Death‐Associated Protein Kinase (DAPK) gene, methylation of the O‐6‐methylguanine‐DNA methyltransferase (MGMT) gene, hypermethylation of the RAS association domain family 1A (RASSF1A) gene promoter region is well‐documented in various cancers, including HNSCC. 38 , 39 , 40 , 41 The detection of p16 gene hypermethylation is often used as a biomarker for the early diagnosis and prognosis of HNSCC (Figure 2 ). Methylation‐specific polymerase chain reaction (MSP) and other molecular techniques are commonly employed to assess the methylation status of the p16 gene in tumor samples.…”

Section: Diagnosis In Personalized Medicinementioning

confidence: 99%

“… 42 The presence of p16 hypermethylation may indicate an increased risk of HNSCC, and also it can act as a potential therapeutic target. 38 Research has shown that the methylation status of the DAPK gene promoter is altered in HNSCC and is associated to its progression, prognosis, and response to therapy. 43 Detecting the hypermethylation of DAPK can have diagnostic and prognostic implications for HNSCC patients.…”

Section: Diagnosis In Personalized Medicinementioning

confidence: 99%

See 4 more Smart Citations

Developments and future prospects of personalized medicine in head and neck squamous cell carcinoma diagnoses and treatments

Jayawickrama,

Ranaweera,

Pradeep

et al. 2024

Cancer Reports

View full text Add to dashboard Cite

BackgroundPrecision healthcare has entered a new era because of the developments in personalized medicine, especially in the diagnosis and treatment of head and neck squamous cell carcinoma (HNSCC). This paper explores the dynamic landscape of personalized medicine as applied to HNSCC, encompassing both current developments and future prospects.Recent FindingsThe integration of personalized medicine strategies into HNSCC diagnosis is driven by the utilization of genetic data and biomarkers. Epigenetic biomarkers, which reflect modifications to DNA that can influence gene expression, have emerged as valuable indicators for early detection and risk assessment. Treatment approaches within the personalized medicine framework are equally promising. Immunotherapy, gene silencing, and editing techniques, including RNA interference and CRISPR/Cas9, offer innovative means to modulate gene expression and correct genetic aberrations driving HNSCC. The integration of stem cell research with personalized medicine presents opportunities for tailored regenerative approaches. The synergy between personalized medicine and technological advancements is exemplified by artificial intelligence (AI) and machine learning (ML) applications. These tools empower clinicians to analyze vast datasets, predict patient responses, and optimize treatment strategies with unprecedented accuracy.ConclusionThe developments and prospects of personalized medicine in HNSCC diagnosis and treatment offer a transformative approach to managing this complex malignancy. By harnessing genetic insights, biomarkers, immunotherapy, gene editing, stem cell therapies, and advanced technologies like AI and ML, personalized medicine holds the key to enhancing patient outcomes and ushering in a new era of precision oncology.

show abstract

Section: Genetic Testingmentioning

confidence: 99%